70results about How to "Reduce cerebral edema" patented technology

The present invention is one kind of Chinese medicine composition for treating cerebral hemorrhage and is preparation process. The Chinese medicine composition consists of effective components from motherwort, giant knotweed, leech, gentian, and buffalo horn or rhinoceros horn; and may be prepared into medicine powder, tincture, capsule, tablet, micro pill and other forms. The Chinese medicine composition has the function of promoting blood circulation to disperse blood clots, and can alleviate hemorrhagic apoplexy cerebral edema, promote the absorption of hematoma and disease focus repair, improve the ischemic and anoxic state of nerve tissue around hematoma, protect damaged brain cell and promote restoring of the nerve function.

The invention provides a pharmaceutical composition for the prevention and treatment of ischemic cerebrovascular diseases and the preparation method thereof, which contains active ingredients and carriers, wherein the active ingredients consist of fumalic acid or the pharmaceutically acceptable salt and borneol with the weight ratio of 100: 0.5 to 10. The invention can be prepared into the pharmaceutical formulations which are applicable to the clinical application, and the formulations include: granules, capsules, tablets, dropping pills, suppositories and injections. The invention reveals the neuro-protective effect of the composition of fumalic acid or the salt and borneol for transient total cerebral ischemia, and the synergy of the two drugs is played by the combination of the two; compared with single fumalic acid, the absorption half-life is prolonged, the time for reaching peak is faster, the dosage of fumalic acid is reduced and the safety of the drugs is increased. The invention has the advantages of the complementary and synergy of pharmacological effects, instant effects, prolonged effective time, small dosage and precise efficacy when being taken as the drug for the prevention and treatment of ischemic cerebrovascular diseases.

The invention relates to a brain fixed-point sub-hypothermia control device. The brain fixed-point sub-hypothermia control device comprises an intrusive guide tube, temperature detection elements, a control system, a liquid cooling device and a liquid pushing device, wherein the temperature detection elements (2, 2') are used for respectively monitoring the temperatures of an inlet and an outlet of the intrusive guide tube (1); the temperature detection element (2'') is used for monitoring the temperature of the output cooling liquid of the liquid cooling device (4); and the control system (3) is used for sending a control signal to start the liquid pushing device (5) to push the cooled liquid into the inlet of the intrusive guide tube at a certain speed. With the adoption of the brain fixed-point sub-hypothermia control device, the brain cooling part can be accurately positioned, the cooling process is timely and quick, and the sub-hypothermia state can be accurately and reliably maintained; in addition, acute and serious cerebral edema can be controlled, and conditions are created for promoting recovery of brain function, so that the brain fixed-point sub-hypothermia control device plays an important role in reducing fatality rate and disability rate.

The invention relates to application of a salvianolic acid A composition in preparing medicines for protecting ischemic brain tissue damage. The composition is prepared from 94-97% of salvianolic acid A, 0.1-1.5% of alkannic acid, 0.1-1.5% of rosmarinic acid, 0.1-1.5% of salvianolic acid B and 0.1-2.0% of salvianolic acid C.

The invention discloses an application of rapamycin of formula (I) in the preparation of a pharmaceutical composition for treating early brain injury after subarachnoid hemorrhage. The present invention proves through experiments that RAP can enhance autophagy, reduce brain edema, reduce the permeability of the blood-brain barrier and alleviate clinical symptoms, thereby alleviating EBI after SAH, and then protecting the brain tissue, providing a basis for the treatment of EBI after SAH A new approach to treatment.

The invention relates to a traditional Chinese medicine pill for curing amenorrhea resulted from psychotropic drugs and a preparation method thereof. The traditional Chinese medicine pill is prepared from the following bulk drugs in parts by weight: 80-100 parts of salvia miltiorrhiza bunge, 80-100 parts of peach kernel, 80-100 parts of safflower, 30-40 parts of cinnamon, 30-40 parts of fennel, 40-60 parts of folium artemisiae argyi, 40-60 parts of rhizoma cyperi, 40-60 parts of radix linderae, 40-60 parts of angelica sinensis, 40-60 parts of szechuan lovage rhizome, 40-60 parts of twotooth achyranthes root, 40-50 parts of rhizoma corydalis, 40-60 parts of bighead atractylodes rhizome and 40-60 parts of poria. The preparation method is as follows: weighting and processing 900g of the bulk drugs in parts by weight; taking 600g of the processed bulk drugs, adding 1200ml of water in the 600g of the processed bulk drugs, decocting for 40 minutes, removing dregs, decocting once again until the decoction liquid boils, decocting by slow fire and concentrating until the volume of the decoction solution is 400ml for later use; and grinding the rest 300g of the bulk drugs into fine powder, and placing the fine powder in a pelleting container, spraying the concentrated liquid in the pelleting container to prepare into water pills, taking the water pills out of the container and drying to obtain the concentrated pills. The traditional Chinese medicine pill is a pure traditional Chinese medicine preparation, has no toxic or side effect, is convenient to take and has low price.

The invention discloses a Chinese medicinal composition for treating cerebral hemorrhage, which relates to the technical field of Chinese medicine. The composition consists of the following components in parts by weight: 8-16 parts of leech, 6-18 parts of giant knotweed, 8-16 parts of astragalus, 6-14 parts of safflower, 10-20 parts of pseudo-ginseng root, 10-20 parts of common selfheal fruit-spike, 10-20 parts of red paeony root, 6-16 parts of chaff flower root, 6-12 parts of ginkgo leaf and 6-18 parts of liquoric root. The Chinese medicinal composition for treating cerebral hemorrhage has the advantages of reasonable composition, short treatment course, high curing rate, no sequelae, safety, reliability and low price. The invention further provides a preparation method for the Chinese medicinal composition for treating cerebral hemorrhage; and the method has a simple process, and is suitable for industrial mass production.

The invention provides application of oxiracetam or levo-oxiracetam in preparation of medicines for preventing or treating neurofunction deficit. The experimental result proves that oxiracetam is obvious in effect of treating ischemic neurofunction deficit caused by cerebral infarction; and the levo-oxiracetam is obvious in effects of treating ischemic neurofunction deficit caused by cerebral infarction and treating neurofunction deficit caused by trauma.

The invention relates to a drug composition for treating encephaledema and a preparation method of the drug composition. The compound drug composition comprises the following active ingredients: sennoside A, cantharidin or a derivative of cantharidin, nimodipine or nifedipine, cinepazide maleate and edaravone. An active drug and a drug combination capable of reducing colloid osmotic pressure and crystal osmotic pressure in brain cells so as to treat the encephaledema are looked for through a cell experiment, and a novel pharmaceutical application is provided clinically.

The Chinese medicine composition for treating apoplexy consists of effective components and pharmaceutically acceptable excipient, and the effective components is prepared with astragalus root, red sage, leech, earthworm and Chuanxiong rhizome. It has the functions of benefiting Qi, dredging meridian and promoting blood circulation to disperse blood clots, and may be used in treating apoplexy, especially apoplexy caused by Qi deficiency and blood clots with the symptoms of hemiplegia, facial hemiplegia, dizziness, etc. The present invention also discloses the preparation process, quality control method and use of the medicine composition.

The invention relates to a disposable counting brain cotton aseptic package tray. A plurality of brain cotton storage grooves for storing new brain cotton or recovering used brain cotton, the size of the brain cotton storage groove can accommodate one brain cotton, a leading wire groove is arranged on one side of each brain cotton storage groove and is used for placing a pull wire of the brain cotton, the leading wire grooves are communicated with the brain cotton storage grooves, a supporting rack or a bonding strip for vertically or obliquely placing the tray is arranged on the back surfaceof the tray, and when the tray is vertically or obliquely placed, the leading wire grooves are positioned below the brain cotton storage grooves. The pull wires are distinguished with the brain cotton, so as to facilitate taking and use; the tray is directly placed or bonded beside a physician operation region, and the brain cotton can be directly picked up in use, so as to reduce intermediate transfer links and shorten operation time; the used brain cotton is placed back the empty brain cotton storage grooves so as to avoid cross contamination, and the amount of the brain cotton is clear so as to improve counting efficiency.

The invention relates to the medicine technical field, and especially relates to an application of Sparstolonin B in the preparation of drugs for treating cerebral hemorrhage. It has been proved by animal experiments that Sparstolonin B has a strong protective effect on mouse brain after cerebral hemorrhage, is capable of prominently repairing the neurologic impairment of mice with cerebral hemorrhage, obviously reliving the cerebral edema, and inhibiting the inflammatory responses around the hematoma tissues, thus increases the survival rate of mice with cerebral hemorrhage, and prominently increases the survival rate of damaged nerve cells of hemoglobin induced microglia. Thus Sparstolonin B can be used to prepare drugs for treating cerebral hemorrhage.

The invention relates to a polypeptide valid target in Ropalidia fasciata insects and application thereof in preventing and treating cerebral thrombosis. The valid target is prepared by the following steps: dialyzing Ropalidia fasciata crude bee venom with a 30kDa dialysis membrane, and carrying out freeze-drying or vacuum concentration and drying on the dialysis solution. A series of pharmacodynamic experiments by people prove that the biotoxin polypeptide valid target and a transdermal absorption preparation thereof have obvious effects on preventing and treating cerebral thrombosis, restoring mobility of animals with cerebral palsy, preventing and treating platelet accumulation and relieving ischemic brain injury, and have better pharmacodynamic performance than Plavix, Xingnaojing injection and other first-tier medicines. The valid target is expected to be used for preparing innovative biochemical medicines for treating cardiovascular and cerebrovascular diseases and for preventing and treating ischemic cardiovascular and cerebrovascular diseases, such as myocardial infarction, cardiovascular thrombosis, cerebral thrombosis, cerebral infarction, acute/chronic cerebral apoplexy, and sequelae caused by cerebral infarction injury, including hemiplegia, hemidysesthesia, hemianopsia, facioplegia, paralysis lingualis, aphasia, pamplegia and the like.

The invention relates to a pharmaceutical composition for treating ischemic cerebral apoplexy and a preparation method and application thereof. The pharmaceutical composition for treating ischemic cerebral apoplexy is prepared from, by weight, 3-12 parts of NADPH and 0.5-8 parts of apocynin. NADPH and apocynin are applied jointly and act cooperatively in a specific proportion, and the pharmaceutical composition can reduce the cerebral infarction volume, significantly relieve the behavior disorder of cerebral ischemia mice, relieve encephaledema, improve the long-term survival capability of mice and enhance neurological function recovery; besides, the treatment effect of the pharmaceutical composition on ischemic cerebral apoplexy is much better than that of NADPH and apocynin which are applied independently on ischemic cerebral apoplexy, and a synergistic effect is achieved when NADPH and apocynin are applied jointly. Thus, the pharmaceutical composition has the effect of treating ischemic cerebral apoplexy and can serve as a potential drug for treating ischemic cerebral apoplexy.

The invention discloses application of miR-486-3p to preparation of a product for treating neuroinflammation caused by SAH. According to the application of a miR-486-3p related biological material topreparation of the following (a1) or (a2) products, (a1) a product for treating SAH is prepared; (a2) a product for inhibiting neuroinflammation caused by SAH is prepared, wherein the related biological material of the miR-486-3p is the miR-486-3p, or an exosome loaded with the miR-486-3p, or a substance capable of promoting expression of the miR-486-3p. Experiments prove that miRNA can be more effectively transferred to the brain by fusing RVG into the exosome modified by membrane glycoprotein Lamp2b to load the miR-486-3p. The miR-486-3p plays an anti-inflammatory role by inhibiting expression of Sirtuin2 (Sirt2).

The invention relates to the field of health care products, and particularly relates to a health care product tonifying the brain and the kidney and a preparation method of the health care product. The health care product comprises the following components in parts by weight: 7-13 parts of artemia, 7-13 parts of ginkgo leaf, 10-20 parts of lucid ganoderma powder, 40-60 parts of camellia powder, 35-55 parts of senega bit boiled with liquorice water, 35-55 parts of acorus tatarinowii, 20-30 parts of morinda officinalis with core removed, 25-35 parts of cortex lycii radicis, and 70-110 parts of white poria. The health care product for tonifying the brain comprises nine medicinal materials, mainly has the functions of nourishing the heart and invigorating the brain, improving the memory and immunity, slowing down ageing, tonifying the brain and soothing the nerves, protecting the heart and tonifying the kidney, and also has auxiliary effects of curing deficiency of the kidney, deficiency of vital energy, fatigue, and deficiency of kidney qi; the health care product has complete nutrition in invigorating the brain, so that a user taking the health care product is full of energy, sleeps well, and has good appetite, enhanced memory and enhanced immunity; and the health care product also can be used for preventing infection of various epidemic diseases.

The invention belongs to the technical field of novel uses of drugs and in particular relates to an application of human albumin in preparing a drug for treating subarachnoid hemorrhage. Confirmed by experiments, the human albumin with a certain concentration can be used for improving early brain injuries after the subarachnoid hemorrhage, including relieving brain edema, lowering the death and the apoptosis of nerve cells and improving the damage to blood brain barrier, thus protecting brain tissues. The application can be used for preparing the drug for treating the subarachnoid hemorrhage, particularly to the drug for treating nerve injury after the subarachnoid hemorrhage.

The invention discloses application of a Chinese medicinal composition in the preparation of a medicament for treating acute severe brain injuries. The medicament of the invention is prepared from ginseng, leech, scorpion, ground beeltle, centipede, red paeony root, borneol, spina date seed and the like and has the effects of boosting qi and activating blood circulation, tracking wind and spasmolysis, and transforming stasis and smoothing veins on collateral damages, stasis obstructing the network vessels of the brain and cranial nerve apraxia of acute brain injuries. Clinical experiments prove that the medicament of the invention has remarkable clinic treatment effects on the acute brain injuries.

Belonging to the technical field of biomedicine, the invention in particular relates to a combination product for prevention and/or treatment of cerebral ischemia and application thereof. The combination product is a pharmaceutical composition containing a Sur1 (sulfonylurea receptor 1) inhibitor and an artemisinin sesquiterpene lactone compound, or a combination of a first agent containing the Sur1 inhibitor and a second agent containing the artemisinin sesquiterpene lactone compound. According to the invention, the Sur1 inhibitor and the artemisinin sesquiterpene lactone compound form the combination product in an appropriate proportion form, have a synergistic effect, and can achieve a better therapeutic effect on cerebral ischemic disease than single use of the Sur1 inhibitor or the artemisinin sesquiterpene lactone compound.